Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience

BJU International

Volumn 104, Issue 9, 2009, Pages 1208-1214

  Diblasio, Christopher J ^a   Malcolm, John B ^a   Hammett, Jessica ^a   Wan, Jim Y ^a,b   Aleman, Michael A ^a   Patterson, Anthony L ^a   Wake, Robert W ^a   Derweesh, Ithaar H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Androgen deprivation therapy; Castration; GnRH; Male; Outcomes; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; GOSERELIN;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SALVAGE THERAPY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CAUSE OF DEATH; GOSERELIN; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 70349973001     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08593.x     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96
2. Huggins C, Hodges CV. Studies on prostate cancer I: the effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941 1 : 293 297
3. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002 52 : 154 179
4. Holmes L Jr Chan W, Jiang Z, Du XL. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer. Prostate Cancer Prostatic Dis 2007 10 : 388 395
5. Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int 2008 101 : 1077 1083
6. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006 106 : 1708 1714
7. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003 95 : 981 989
8. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005 103 : 1615 1624 (Pubitemid 40490022)
9. Derweesh IH, DiBlasio CJ, Kincade MC et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 2007 100 : 1060 1065
10. Diblasio CJ, Malcolm JB, Derweesh IH et al. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int 2008 102 : 39 43
11. Malcolm JB, Derweesh IH, Kincade MC et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 2007 14 : 3551 3559
12. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006 175 : 136 9
13. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006 91 : 1305 1308
14. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 4th edn. Philadelphia : Lippincott-Raven, 1992
15. D'Amico A, Moul J, Kattan MW. Emerging prognostic factors for outcome prediction in clinically localized prostate cancer: prostate-specific-antigen level, race, molecular markers, and neural networks. In Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, Comprehensive Textbook of Genitourinary Oncology, 2nd edn. Philadelphia : Lippincott Williams & Wilkins, 2000 : 680 700
16. Lee LN, Barnswell C, Torre T, Fearn P, Kattan M, Potters L. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses. Int J Radiat Oncol Biol Phys 2002 53 : 282 289
17. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997 337 : 295 300
18. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999 341 : 1781 1788
19. Derweesh IH, Kupelian PA, Zippe C et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 2004 22 : 300 306
20. Powell IJ, Dey J, Dudley A et al. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology 2002 59 : 907 912
21. Tewari A, Horninger W, Pelzer AE et al. Factors contributing to the racial differences in prostate cancer mortality. BJU Int 2005 96 : 1247 1252
22. Lu-Yao GL, Albertsen PC, Moore DF et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008 300 : 173 181
23. Studer UE, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006 24 : 1868 1876
24. Bhandari MS, Crook J, Hussain M. Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 2005 23 : 8212 8218
25. Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int 2007 100 : 738 743
26. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 2007 99 (Suppl. 1 19 24
27. Cooperberg MR, Lubeck DP, Penson DF, Mehta SS, Carroll PR, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol 2003 170 : 905 908
28. Singer EA, Golijanin DJ, Messing EM. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged? Can J Urol 2008 15 : 4381 4387
29. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 360 : 103 106
30. U.S. Census Bureau. Shelby County, Tennessee; State and County QuickFacts 2005. Available at: http://quickfacts.census.gov/qfd/states/47000.html. Accessed March 2009
31. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006 24 : 4448 4456
32. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007 110 : 1493 1500